Cesarean scar pregnancy (CSP) is a very rare and specific type of ectopic pregnancy with an incidence of 1 in 1800 to 1 in 2216 and is one of the distant complications of cesarean delivery. The endogenous type: the amniotic sac is implanted in the scar and grows in the isthmus and in the uterine cavity. This can progress to live birth, but it also increases the risk of haemorrhage at the implantation site, with some cases forming a hypoplastic or placenta praevia, and the lack of muscle fibers here prevents effective haemostasis, resulting in uncontrollable haemorrhage. Ectopic type: The gestational sac is deeply implanted in the caesarean incision scar and grows towards the myometrium, leading to uterine rupture or hemorrhage in the early stages. The condition is variable and even if the diagnosis is clear, treatment is relatively difficult. Although the incidence of CSP is low, the incidence of scar pregnancy has been on the rise in recent years as the rate of cesarean delivery has increased, and the risk of uncontrollable vaginal hemorrhage with CSP is extremely high, leading to loss of the ability to carry a pregnancy to term and directly affecting the quality of life of young patients. At present, there is no optimal clinical treatment for CSP, and the misdiagnosis rate is high; once diagnosed, pregnancy should be terminated as soon as possible. Therefore, accurate early diagnosis and effective treatment are the key to preserving the uterus and fertility. There is no uniform treatment standard for cesarean scar pregnancy, and the main treatment methods are surgery and conservative treatment, but traditional conservative treatment is difficult to avoid the risk of surgical removal of the uterus. In recent years, with the development of minimally invasive interventional techniques, arterial embolization has opened up a new treatment route for cesarean scar pregnancy, while uterine artery chemoembolization increases the local MTX blood concentration in the blastocyst on the basis of arterial embolization, effectively killing and eliminating embryonic tissues to achieve the dual effect of reducing bleeding and improving the efficacy. Uterine artery embolization (UACE) has been used in the treatment of obstetrical and gynecological diseases such as uterine fibroids and postpartum hemorrhage since the 1990s. In recent years, with the development of interventional techniques, minimally invasive, safe and effective uterine artery embolization has been widely used in the treatment of CSP by scholars at home and abroad, which can effectively control vaginal haemorrhage and reduce the risk of hysterectomy. Meanwhile, intrauterine artery infusion of methotrexate (MTX) can increase the local drug concentration, improve the effect of embryocide, and provide the necessary conditions to preserve the uterus and reproductive function of the patient for later clearance treatment by rapidly and effectively stopping hemorrhage.